[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Identifieur interne : 000098 ( Ncbi/Checkpoint ); précédent : 000097; suivant : 000099[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Auteurs : P. Damier [France] ; L. Tremblay ; J. Féger ; E C HirschSource :
- Revue neurologique [ 0035-3787 ] ; 2000.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Biological Transport, Active (physiology), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (etiology), Enkephalins (drug effects), Enkephalins (metabolism), Haplorhini, Humans, Levodopa (adverse effects), Levodopa (pharmacokinetics), Neural Pathways (drug effects), Neural Pathways (metabolism), Neuronal Plasticity (physiology), Neurons, Efferent (drug effects), Neurons, Efferent (metabolism), Parkinson Disease (drug therapy), Receptors, Dopamine D2 (drug effects), Receptors, Dopamine D2 (metabolism), Substance P (drug effects), Substance P (metabolism), Time Factors.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , drug effects : Enkephalins, Receptors, Dopamine D2, Substance P.
- chemical , metabolism : Enkephalins, Receptors, Dopamine D2, Substance P.
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- diagnosis : Dyskinesia, Drug-Induced.
- drug effects : Corpus Striatum, Neural Pathways, Neurons, Efferent.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- metabolism : Corpus Striatum, Neural Pathways, Neurons, Efferent.
- physiology : Biological Transport, Active, Neuronal Plasticity.
- Animals, Disease Models, Animal, Haplorhini, Humans, Time Factors.
Abstract
L-DOPA-induced dyskinesias are one of the main problems encountered in treating patients with Parkinson's disease (PD). They are induced by the antiparkinsonian medications and primarily related to the degree of dopaminergic depletion, as shown by the fact that they tend to appear several years after the onset of the disease. Do the initial therapeutic decisions taken in treating a PD patient influence the point at which dyskinesias first occur? This question is raised in view of the apparent priming phenomenon that occurs in first exposure to L-DOPA. L-DOPA administrated to an MPTP intoxicated monkey rapidly corrects the animals' motor symptoms but generate dyskinesias. In contrast, the administration of dopaminergic agonists with a long half-life has a similar therapeutic effect but without inducing dyskinesias. However, a parkinsonian monkey that had received L-DOPA and developed dyskinesias, which were subsequently abolished when the treatment was withdrawn for several months, proceeded to develop dyskinesias when treatment with dopaminergic agonists with long half-life was introduced. The monkeys' previous exposure to L-DOPA (i.e. priming) thus increased its susceptibility to develop dyskinesias after exposure to drugs which would not otherwise have had this effect. Pulsatile activation of type D2 dopamine receptors is reported to be the principal factor in the triggering of dyskinesias and may well be involved in the priming phenomenon. While the pathophysiological basis of priming is not yet known, the phenomenon would not appear to be related to a hyperexpression of dopamine receptors (types D1 and D2) in the sensorimotor striatum. The results of recent experiments have given rise to several different hypothesis for the mechanisms involved in priming: the role of internalization of dopamine receptors after administration of dopaminergic drugs; change in the distribution of D3 dopamine receptor; changes in the expression of peptides (substance P, enkephalin) in efferent neurons of the striatum; and reorganization of connections at the level of the dopaminergic neurons and their target tissue. While many questions remain unanswered, it may well be that the initial therapeutic decisions taken when treating de novo patient are crucial in trying to delay the onset of dyskinesias.
PubMed: 10740093
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001345
- to stream PubMed, to step Curation: 001304
- to stream PubMed, to step Checkpoint: 001304
- to stream Ncbi, to step Merge: 000098
- to stream Ncbi, to step Curation: 000098
Links to Exploration step
pubmed:10740093Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre d'Investigation Clinique, INSERM U289, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, INSERM U289, Groupe Hospitalier Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tremblay, L" sort="Tremblay, L" uniqKey="Tremblay L" first="L" last="Tremblay">L. Tremblay</name>
</author>
<author><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10740093</idno>
<idno type="pmid">10740093</idno>
<idno type="wicri:Area/PubMed/Corpus">001345</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001345</idno>
<idno type="wicri:Area/PubMed/Curation">001304</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001304</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001304</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001304</idno>
<idno type="wicri:Area/Ncbi/Merge">000098</idno>
<idno type="wicri:Area/Ncbi/Curation">000098</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000098</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].</title>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre d'Investigation Clinique, INSERM U289, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Investigation Clinique, INSERM U289, Groupe Hospitalier Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tremblay, L" sort="Tremblay, L" uniqKey="Tremblay L" first="L" last="Tremblay">L. Tremblay</name>
</author>
<author><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Biological Transport, Active (physiology)</term>
<term>Corpus Striatum (drug effects)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Disease Models, Animal</term>
<term>Dyskinesia, Drug-Induced (diagnosis)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Enkephalins (drug effects)</term>
<term>Enkephalins (metabolism)</term>
<term>Haplorhini</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (pharmacokinetics)</term>
<term>Neural Pathways (drug effects)</term>
<term>Neural Pathways (metabolism)</term>
<term>Neuronal Plasticity (physiology)</term>
<term>Neurons, Efferent (drug effects)</term>
<term>Neurons, Efferent (metabolism)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Receptors, Dopamine D2 (drug effects)</term>
<term>Receptors, Dopamine D2 (metabolism)</term>
<term>Substance P (drug effects)</term>
<term>Substance P (metabolism)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Enkephalins</term>
<term>Receptors, Dopamine D2</term>
<term>Substance P</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Enkephalins</term>
<term>Receptors, Dopamine D2</term>
<term>Substance P</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Neurons, Efferent</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Neurons, Efferent</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Biological Transport, Active</term>
<term>Neuronal Plasticity</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Haplorhini</term>
<term>Humans</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">L-DOPA-induced dyskinesias are one of the main problems encountered in treating patients with Parkinson's disease (PD). They are induced by the antiparkinsonian medications and primarily related to the degree of dopaminergic depletion, as shown by the fact that they tend to appear several years after the onset of the disease. Do the initial therapeutic decisions taken in treating a PD patient influence the point at which dyskinesias first occur? This question is raised in view of the apparent priming phenomenon that occurs in first exposure to L-DOPA. L-DOPA administrated to an MPTP intoxicated monkey rapidly corrects the animals' motor symptoms but generate dyskinesias. In contrast, the administration of dopaminergic agonists with a long half-life has a similar therapeutic effect but without inducing dyskinesias. However, a parkinsonian monkey that had received L-DOPA and developed dyskinesias, which were subsequently abolished when the treatment was withdrawn for several months, proceeded to develop dyskinesias when treatment with dopaminergic agonists with long half-life was introduced. The monkeys' previous exposure to L-DOPA (i.e. priming) thus increased its susceptibility to develop dyskinesias after exposure to drugs which would not otherwise have had this effect. Pulsatile activation of type D2 dopamine receptors is reported to be the principal factor in the triggering of dyskinesias and may well be involved in the priming phenomenon. While the pathophysiological basis of priming is not yet known, the phenomenon would not appear to be related to a hyperexpression of dopamine receptors (types D1 and D2) in the sensorimotor striatum. The results of recent experiments have given rise to several different hypothesis for the mechanisms involved in priming: the role of internalization of dopamine receptors after administration of dopaminergic drugs; change in the distribution of D3 dopamine receptor; changes in the expression of peptides (substance P, enkephalin) in efferent neurons of the striatum; and reorganization of connections at the level of the dopaminergic neurons and their target tissue. While many questions remain unanswered, it may well be that the initial therapeutic decisions taken when treating de novo patient are crucial in trying to delay the onset of dyskinesias.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
<name sortKey="Tremblay, L" sort="Tremblay, L" uniqKey="Tremblay L" first="L" last="Tremblay">L. Tremblay</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000098 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000098 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= pubmed:10740093 |texte= [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:10740093" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |